- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Terrill Jordan: The Promise, and the Reality, of Biosimilars
Terrill Jordan, chief executive officer of Regional Cancer Care Associates (RCCA), discusses how RCCA is handling biosimilar availability.
Transcript
Biosimilars, you know, there's a lot of promise there. What we found at [Regional Cancer Care Associates, RCCA] when we looked at biosimilars is that the promise was probably more than what we'll actually see in practice. Biosimilars that take a lot of money to develop, at the end of the day, they're in the same place, many times, as the reference drug, maybe 15% to 20% cheaper.
So it's not the move you would expect from a value-based standpoint. So what I really expect we’ll see is that pricing will stabilize when you have a biosimilar because it will introduce competition, but I don't expect we'll see significant price decreases. These are not generics. So [with] a generic, the price will drop precipitously. We're not going to see that. We’ll see stabilization of price because of the competition. The more biosimilars in a particular category, the more, I think, stabilization you'll see.
So I think that's what we'll see. From our perspective, I actually just talked about our chairman this morning, and one of the things that we're looking at is, you know, how can we kind of push the value out of it? And that will be the piece that we’ll continue to kind of struggle with: how do we pull value out of that, instead of just price stability?
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
